Table 1. Patient characteristics and ongoing treatment * .
| Age | Gender | SLEDAI | Disease activity at visit: organ | dsDNA (IU/ml) | ENA | Medication | History of nephritis |
|---|---|---|---|---|---|---|---|
| 46 | F | 8,0 | serology, alopecia, kidney (dysmorphic erythrocytes) | 75,0 | SS-A, SS-B, nucleosomes, PM-Scl | HCQ, Aza, Pred (10mg) | yes |
| 46 | F | 2,0 | serology | 0,0 | SS-A, SS-B | HCQ | no |
| 33 | F | 2,0 | serology | 100,0 | none | none | no |
| 53 | F | 2,0 | serology | 80,0 | none | HCQ, Aza, Pred (10mg) | yes |
| 39 | F | 2,0 | serology | 12,0 | none | HCQ, Pred (7,5mg) | no |
| 39 | F | 7,0 | serology, hematology, skin | 200,0 | SS-A, histones, nucleosomes, Sm, RibP | HCQ, Aza, Pred (5mg) | no |
| 58 | F | 0,0 | none | 0,6 | SS-A | HCQ, Aza, Pred (5mg) | yes |
| 32 | F | 4,0 | serology, skin | 25,0 | SS-A, SS-B, histones, Sm, RibP | Aza, Pred (5mg) | yes |
| 51 | F | 6,0 | serology, kidney (dysmorphic erythrocytes) | 1,8 | none | Aza, Pred (5mg) | yes |
| 36 | F | 4,0 | serology | 65,0 | none | Aza, Pred (10mg) | yes |
| 53 | F | 3,0 | serology, hematolgoy | 8,9 | SS-A, SS-B | HCQ | no |
| 27 | F | 5,0 | serology, hematology, skin | 3,6 | SS-A | HCQ | no |
| 55 | F | 4,0 | serology | 22,0 | none | MMF, Pred (10mg) | yes |
| 30 | F | 2,0 | serology | 39,0 | none | Pred (5mg) | yes |
| 21 | F | 4,0 | serology | 75,0 | histones, Sm | HCQ, Aza, Pred (10mg) | yes |
| 52 | M | 3,0 | serology, hematology | 8,9 | none | HCQ, Aza, Pred (10mg) | no |
| 51 | F | 4,0 | serology | 16,0 | SS-A, nucleosomes | HCQ, MTX (15mg) | no |
*
SLEDAI: SLE disease activity index, dsDNA: double-stranded DNA, ENA: extractable nuclear antigens, Sm: Smith antigen, SS-A: Sjoegren Syndrome Antigen A, SS-B: Sjoegren Syndrome Antigen B, PM-Scl: Polymyositis-Scleroderma, RibP: Ribosomal antigen P, HCQ: Hydroxychloroquine, Aza: Azathioprine, Pred: Prednisone, MMF: Mycophenolate Mofetil, MTX: Methotrexate